US FDA approves Rybrevant plus chemotherapy to treat EGFR mutated NSCLC
The FDA approval is based on results from the Phase 3 PAPILLON study, which showed Rybrevant plus chemotherapy…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Mar 24
The FDA approval is based on results from the Phase 3 PAPILLON study, which showed Rybrevant plus chemotherapy…
27 Feb 24
The approval allows the oral suspension to be utilised in treating CLL/ SLL, WM, and cGVHD following the…
27 Feb 24
The latest expanded indication of Biktarvy pertains to the treatment of individuals with HIV who are known or…
26 Feb 24
Simlandi is the first citrate-free, high-concentration biosimilar to be designated interchangeable with Humira in the US, and is…
21 Feb 24
The US regulator approved the company’s supplemental Biologics License Application (sBLA) for the reduced, bi-weekly dosing of Tecvayli…
20 Feb 24
The EC approval of Velsipity was supported by results from the Phase 3 ELEVATE UC registrational programme, which…
19 Feb 24
The FDA approval is based on data from the Phase 3 OUtMATCH study, which showed a high proportion…
19 Feb 24
The approval was based on the findings from the FLAURA2 trial in which Tagrisso with chemotherapy reduced the…
15 Feb 24
The effectiveness of iloprost in treating severe frostbite was determined by an open-label, controlled trial in which none…
13 Feb 24
The FDA approval was based on efficacy and safety findings from two multicentre, randomised, double-blind, parallel-group, placebo-controlled 12-week…